-
公开(公告)号:US20130074201A1
公开(公告)日:2013-03-21
申请号:US13621460
申请日:2012-09-17
申请人: Scott Kern , Francesca Scrimieri
发明人: Scott Kern , Francesca Scrimieri
IPC分类号: A61K39/395 , C12N15/63 , C12N1/21 , C12N1/19 , C12N5/10 , C12P21/02 , G01N33/574 , C12Q1/68 , C12N15/113 , C07K16/18 , A61K31/7088 , A61K48/00 , A61P35/00 , A01K67/027 , C12N15/12
CPC分类号: A61K31/713 , C07K14/47 , C07K16/32 , C12N15/113 , C12N2310/11 , C12N2310/14 , C12N2310/16 , C12Q1/6886 , C12Q2600/156 , G01N33/5011 , G01N33/57484 , G01N2500/10
摘要: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods useful for treating cancer characterized by the expression of mutant FAM190A proteins. In a specific embodiment, a method for treating a patient having a cancer characterized by a FAM190A intragenic rearrangement comprises the step of administering to the patient an agent that inhibits a biological function or reduces the level or expression of the FAM190A protein.
摘要翻译: 本发明涉及癌症领域。 更具体地,本发明提供了用于治疗癌症的组合物和方法,其特征在于突变型FAM190A蛋白的表达。 在具体实施方案中,用于治疗患有以FAM190A基因内重排为特征的癌症的患者的方法包括向患者施用抑制生物学功能或降低FAM190A蛋白的水平或表达的药剂的步骤。